| Antitope Ltd Announces EpiScreen™ Collaboration With Centocor Inc |
|
19 November 2007, Cambridge (UK) - Antitope Ltd., today announced they have entered into a research collaboration with Centocor Inc.. The research collaboration will employ Antitope's EpiScreenTM technology to assist Centocor in evaluating the immunogenicity of protein therapeutic leads for future development.
"We are delighted to be working with Centocor and in providing them with tests for preclinical assessment of immunogenicity." said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope Limited, adding " we hope that the addition of EpiScreenTM to other preclinical assays will assist Centocor in their selection of therapeutic leads with low immunogenicity potential." About Antitope Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity. Antitope's proprietary EpiScreenTM technology builds upon the previous pioneering work of its founders in the detection and removal of T cell epitopes in proteins. Antitope are a privately-held company and have established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit http://www.antitope.co.uk/. For further information contact: Dr Neil Butt Business Development Director Tel: +44 (0)1223 496190 Email: neil.butt@antitope.co.uk |